JP2019511483A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511483A5
JP2019511483A5 JP2018545910A JP2018545910A JP2019511483A5 JP 2019511483 A5 JP2019511483 A5 JP 2019511483A5 JP 2018545910 A JP2018545910 A JP 2018545910A JP 2018545910 A JP2018545910 A JP 2018545910A JP 2019511483 A5 JP2019511483 A5 JP 2019511483A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
cycloalkyl
pharmaceutical composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018545910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020451 external-priority patent/WO2017151922A1/en
Publication of JP2019511483A publication Critical patent/JP2019511483A/ja
Publication of JP2019511483A5 publication Critical patent/JP2019511483A5/ja
Pending legal-status Critical Current

Links

JP2018545910A 2016-03-02 2017-03-02 免疫療法のためのsting活性化ナノワクチン Pending JP2019511483A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302637P 2016-03-02 2016-03-02
US62/302,637 2016-03-02
PCT/US2017/020451 WO2017151922A1 (en) 2016-03-02 2017-03-02 Sting activating nanovaccine for immunotherapy

Publications (2)

Publication Number Publication Date
JP2019511483A JP2019511483A (ja) 2019-04-25
JP2019511483A5 true JP2019511483A5 (enExample) 2020-04-09

Family

ID=59743242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545910A Pending JP2019511483A (ja) 2016-03-02 2017-03-02 免疫療法のためのsting活性化ナノワクチン

Country Status (9)

Country Link
US (1) US11376324B2 (enExample)
EP (1) EP3423044A4 (enExample)
JP (1) JP2019511483A (enExample)
KR (1) KR20180114946A (enExample)
CN (1) CN109069440A (enExample)
AU (1) AU2017225769B2 (enExample)
CA (1) CA3016457A1 (enExample)
MX (1) MX2018010586A (enExample)
WO (1) WO2017151922A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3429596B1 (en) 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
KR102569881B1 (ko) 2016-07-06 2023-08-22 에프-스타 테라퓨틱스 인코포레이티드 질병 치료용 화합물, 조성물 및 방법
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019090343A1 (en) * 2017-11-06 2019-05-09 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
US11813326B2 (en) * 2018-01-04 2023-11-14 Academia Sinica Cell-associating immunologic adjuvants for treatment enhancement
BR112020013405A2 (pt) * 2018-01-25 2020-12-01 Acm Biolabs Pte Ltd. polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
JP2021512144A (ja) * 2018-01-26 2021-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California 環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
US10947227B2 (en) 2018-05-25 2021-03-16 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US12291548B2 (en) 2018-07-10 2025-05-06 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN109453364B (zh) * 2018-09-30 2021-10-15 郑州大学第一附属医院 一种双重响应性纳米颗粒及其在肿瘤抑制中的应用
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
EP3934757B1 (en) * 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020243217A1 (en) * 2019-05-28 2020-12-03 The Board Of Regents Of The University Of Texas System pH RESPONSIVE COMPOSITIONS AND USES THEREOF
AU2020303968A1 (en) 2019-06-22 2022-01-27 The Board Of Regents Of The University Of Texas System Biodegradable ultra-pH sensitive polymers
JP7660568B2 (ja) * 2019-11-07 2025-04-11 サムヤン ホールディングス コーポレイション 免疫誘導用ポリマーナノ粒子組成物及びその製造方法
EP4061428A4 (en) * 2019-11-18 2023-12-20 Onconano Medicine, Inc. Ph responsive compositions, formulations, and methods of imaging a tumor
GB201918963D0 (en) 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
CN111184738B (zh) * 2020-03-04 2021-05-28 北京大学 一种二嵌段共聚物或其药学上可接受的盐在制备抗病毒药物中的应用、药物组合物
CN113577255B (zh) * 2020-04-30 2023-09-08 中国科学院上海药物研究所 肿瘤纳米疫苗、其制备方法及用途
BR112023004271A2 (pt) * 2020-09-08 2023-04-04 Univ Texas Composições de ativação de sting polivalentes e usos das mesmas
WO2023018743A1 (en) * 2021-08-10 2023-02-16 Wisconsin Alumni Research Foundation Ph-responsive nanoparticle for delivery of ribonucleoproteins
EP4470560A4 (en) * 2022-01-26 2026-01-14 Pingshan Translational Medicine Center Shenzhen Bay Laboratory TUMOR IMMUNOTHERAPY
CN119775506A (zh) * 2022-02-16 2025-04-08 北京大学 聚合物在制备用于结合膜结构的组合物中的用途
WO2024226815A2 (en) * 2023-04-28 2024-10-31 University Of Washington B-cell epitopes of treponema pallidum antigens for use in a syphilis vaccine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579945A (en) 1982-04-29 1986-04-01 Ribi Immunochem Research, Inc. Purification of trehalose dimycolates
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505899A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4435386A (en) 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505900A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4950645A (en) 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
WO2002030931A2 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CN1370601A (zh) * 2001-02-22 2002-09-25 中国科学院成都有机化学研究所 单剂基因工程乙肝疫苗缓释微球的制备方法
US9200036B2 (en) * 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004006837A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
ES2259914B1 (es) * 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
AU2006243960A1 (en) * 2005-05-10 2006-11-16 Emory University Strategies for delivery of active agents using micelles and particles
AU2008231424A1 (en) * 2007-03-28 2008-10-02 National Institute Of Immunology Polymer particles based vaccine
CA2688346A1 (en) * 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
WO2010120385A1 (en) * 2009-04-18 2010-10-21 Massachusetts Institute Of Technology pH SENSITIVE BIODEGRADABLE POLYMERIC PARTICLES FOR DRUG DELIVERY
CN107252482A (zh) * 2009-05-27 2017-10-17 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
CA2811692C (en) * 2010-09-22 2020-02-18 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9511152B2 (en) * 2012-04-05 2016-12-06 The Board Of Regents Of The University Of Texas System Multicolored pH-activatable fluorescence nanoplatform
MX361680B (es) * 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
EP3623361B1 (en) 2013-12-19 2021-08-18 Novartis AG Lipids and lipid compositions for the delivery of active agents
MX2016016135A (es) * 2014-06-06 2017-10-20 Univ Texas Biblioteca de polimeros que responden al ph y nanosondas de estos.
US11247968B2 (en) * 2015-09-14 2022-02-15 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
CN105214097A (zh) * 2015-10-30 2016-01-06 中国科学院福建物质结构研究所 一种口服纳米疫苗运载体的免疫实施与检测技术
US11096899B2 (en) * 2018-09-07 2021-08-24 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment

Similar Documents

Publication Publication Date Title
JP2019511483A5 (enExample)
JP2020508310A5 (enExample)
US11376324B2 (en) Sting activating nanovaccine for immunotherapy
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
JP2020532532A5 (enExample)
JP2019519503A5 (enExample)
ES2522042T3 (es) Composición de vacuna que comprende un ARN modificado con caperuza 5'
JP2021104038A5 (enExample)
JP2019088286A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2017186337A5 (enExample)
JP2017538682A5 (enExample)
JP2009536191A5 (enExample)
JP2018537975A5 (enExample)
JP2016503029A5 (enExample)
JP2017526677A5 (enExample)
JP2008528671A5 (enExample)
JP2015536954A5 (enExample)
JP2012162567A5 (enExample)
JP6293882B2 (ja) 遺伝的に安定な腫瘍溶解性rnaウイルス、その製造方法およびその使用
JP2020506884A5 (enExample)
Ghazizadeh et al. Advances in cancer nanovaccines: a focus on colorectal cancer
RU2019114370A (ru) Нуклеотидная последовательность, экспрессирующая якорный белок экзосом для применения в качестве вакцины
JP2018537433A5 (enExample)
JPWO2020051356A5 (enExample)